July 10, 2020
Among younger patients with chronic lymphocytic leukemia (CLL) receiving one of the four most common treatment regimens, 59% experienced at least one incident adverse event, according to a study in Advances in Therapy.
The retrospective cohort study included 1706 adults with commercial insurance in the United States who received CLL treatment between November 1, 2013, and May 31, 2018. Among them, the median age was 58, and 27% received bendamustine–rituximab, 27% received ibrutinib monotherapy, 19% received rituximab monotherapy, and 16% received fludarabine combined with cyclophosphamide and rituximab.
Overall, 59% of patients had one or more adverse events, according to the study: 62% with bendamustine–rituximab, 60% with ibrutinib monotherapy, 25% with rituximab monotherapy, and 79% with fludarabine combined with cyclophosphamide and rituximab.
“Mean total all-cause healthcare cost over follow-up was $13,858 ± 14,626 per patient per month [PPPM],” researchers reported. “Increased number of adverse events was associated with increased odds of hospitalization (odds ratio = 2.9; 95% confidence interval [CI] 2.5–3.4) and increased mean cost PPPM (cost ratio = 1.2; 95% CI 1.1–1.2).”
Researchers advised further investigations into the risks, benefits, and value of novel therapies to treat patients with CLL as the use of such agents in the United States continues to grow.
Kabadi SM, Near A, Wada K, Burudpakdee C. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study [published correction appears in Adv Ther. 2020 Jun 13;:]. Adv Ther. 2020;37(7):3129-3148. doi:10.1007/s12325-020-01350-w